Leslie – Interview 43
Leslie took part in a placebo-controlled drug trial of rofecoxib (Vioxx) for prostate cancer prevention. He became extremely ill, but doctors monitoring his progress did not pick up his symptoms. He took the drug company to court, and won compensation.
Leslie was 70 in 2003 when he was invited by his GP to take part in a randomised placebo-controlled trial of rofecoxib (Vioxx) as a way of preventing prostate cancer, run by a pharmaceutical company. He was in good health, but aware of the dangers of prostate cancer for men of his age. His GP advised him that the drug should be quite safe. So he decided to take part, partly to help other men who might be affected by prostate cancer and partly because of the personal benefit of having regular check-ups during the six years of the trial.
Within the first few months of starting the tablets in December 2003, Leslie became increasingly unwell. He developed severe gastro-intestinal (GI) problems, including bloody diarrhoea and faecal incontinence, and had no appetite. He stopped taking the tablets at one point in May 2004, but his GP advised him to start taking them again, and to take an over-the counter remedy for diarrhoea. Even though blood tests showed many abnormal results, no immediate action was taken and in early June he was asked to come back again in a fortnight for a further test.
However, Leslie’s health declined rapidly and on June 9th he developed uncontrolled shaking and was taken to hospital in an ambulance. Staff at the hospital asked for the tablets to be unblinded; so they could check whether Leslie had been taking rofecoxib rather than the placebo (which he had). They immediately stopped the tablets. He was found to have a temperature of 104.9°, exceptionally low blood pressure, an abnormal heart action, severe dehydration and septicaemia. It was discovered his colon was bleeding. Gastro-intestinal bleeding was a known, though very rare, side-effect of rofecoxib, and the trial supervisor had previously noted GI bleed?; as a possibility in Leslie’s notes, but had not referred him to hospital. A specialist GI nurse later told Leslie that anyone with blood in their faeces should be referred and investigated within 14 days.
Although Leslie survived, he has been left with ulcerative colitis, a disease that causes ulcers in the lining of the rectum and colon, and he remained very ill for many months after discharge. This has had a particular impact on his wife, who watched him becoming more and more ill and feared for his life. Leslie feels without her care and support he might not be here today.
He was at first offered £2000 compensation, then £3000, but decided on his GP’s advice to contact a legal adviser and take his compensation claim to court. It took over four years to get a judgement in his favour, in which the judge ruled that, on the balance of probability, rofecoxib was likely to have been a significant cause of Leslie’s illness. The drug company originally announced it would appeal but eventually agreed £28,000 compensation in an out-court settlement. Rofecoxib was withdrawn from the market in September 2004 because of concerns about the increased risk of heart attack and stroke. Despite the judge’s ruling, the company still maintains that Leslie’s GI bleeding was not caused by the drug.
Looking back, Leslie feels his consent was not properly informed, and argues that there was already enough evidence to know that rofecoxib could have serious side-effects, but he was reassured by doctors that the drug was safe. He has major concerns about the organisation and funding of trials, and felt the staff involved were mainly driven by the need to enrol more patients and keep them in the trial, rather than his individual care needs. He feels his condition should have been more closely monitored, and that anybody who becomes as ill as he did should be withdrawn from a trial at once. Looking back he wishes he had withdrawn himself, but he trusted the doctors; advice. Personally he would never take part in a trial again, and advises people to look very carefully and critically at any information they are given.